ARCB vs BMY · P/E 11, rev $2.18B vs P/E 17, rev $24.46B
ArcBest Corp (ARCB) versus Bristol-Myers Squibb Company (BMY) — a side-by-side from cached financials, not a winner call.
ArcBest Corp (ARCB) is a trucking company listed on US.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Latest reported ARCB revenue for 2026-06-30 was $2.18B. Net income was -$14.9M. ARCB currently screens at market cap $1.94B and trailing P/E 11.2.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
ARCB currently screens at market cap $1.94B and trailing P/E 11.2. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Not investment advice. Open the ARCB and BMY stock pages for the full models.
Not investment advice.